http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I700088-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2018-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c0a8071cd8a9920ac98bd9f90db890f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4b5d0b7fc6ad5d783bb57033e07f14b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_542499e1aabfff298399ee3f5f35b84f |
| publicationDate | 2020-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-I700088-B |
| titleOfInvention | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) |
| abstract | The application refers to a novel combination treatment/ combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I ,nwherein Ring A nis a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms andnwherein R nis Cl and wherein R nmay be located either in the para-, meta- or ortho-position of Ring A n,nwherein S* nis a sulphur atom that represents a chiral centernor a pharmaceutically acceptable salt thereof.nHereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III nor a pharmaceutically acceptable salt thereof. |
| priorityDate | 2017-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 274.